Travere Therapeutics, Inc. today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS ...

Monarch Healthcare Management, a Minnesota-based provider of senior care services, is proud to announce that seven of its long-term care communities have been named recipients of the 2025 Bronze ?

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price objective lowered by Needham & Company LLC from $153.00 to $150.00 in a report published on Monday,Benzinga reports. The brokerage ...

FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...

In response to the FDA's feedback, Axsome plans to conduct an additional controlled trial that will use a fixed-dose paradigm ...

Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target ...

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...